Cutaneous squamous cell carcinoma (CSCC) is no longer a disease managed solely by the scalpel. As the second most common form of skin cancer worldwide, it has long presented a growing public health challenge, particularly for our aging population and immunosuppressed patients. However, we are currently witnessing a seismic shift in how oncologists approach high-risk, resectable cases.
The Failure of “One-Size-Fits-All” Staging
A major hurdle in CSCC management is our reliance on legacy staging systems. Tools like the AJCC and BWH classifications were designed long before the era of immunotherapy. They often overlook critical biological markers—such as the tumor microenvironment, growth dynamics, and patient-specific immune status—that dictate how a cancer will behave.
This creates a clinical paradox: two patients with the same stage of disease may face vastly different outcomes. Until we adopt a biologically informed, CSCC-specific framework, we risk overtreating some patients while failing to provide enough support to others.
Adjuvant vs. Neoadjuvant: The Battle for Strategy
The debate between adjuvant (post-surgery) and neoadjuvant (pre-surgery) immunotherapy is heating up. While adjuvant therapy aims to mop up remaining cells after surgery, the results have been mixed at best.
- The C-POST Success: In high-risk cohorts, adjuvant cemiplimab showed a significant reduction in recurrence, with 24-month disease-free survival (DFS) hitting 87.1% compared to 64.1% for the placebo group.
- The KEYNOTE-630 Setback: Conversely, the KEYNOTE-630 trial for adjuvant pembrolizumab was terminated for futility, failing to show a significant improvement in overall survival.
Why the discrepancy? Experts suggest that patient selection is the culprit. Adjuvant therapy often treats patients who may have already been cured by surgery alone, leading to unnecessary toxicity.
Why Neoadjuvant Immunotherapy is Stealing the Spotlight
The most exciting trend in oncology is the move toward neoadjuvant PD-1 blockade. By administering immunotherapy before the tumor is removed, we prime the immune system to recognize tumor antigens while the primary mass is still present.
The data is compelling. Across multiple studies, we are seeing major pathological response (MPR) rates consistently between 50% and 70%. In some cases, patients are achieving a complete pathological response (pCR), meaning no viable tumor cells remain by the time they reach the operating table.
Did You Know?
In many neoadjuvant trials, there is a poor correlation between what doctors see on a scan and what is found during pathology. A tumor might look “stable” on an MRI, yet show near-total eradication when examined under a microscope.
The Future: Surgery De-escalation
Could we soon be performing less surgery? Trials like MATISSE and De-Squamate are testing exactly that. By using immunotherapy to shrink or eradicate tumors, surgeons can avoid radical, disfiguring procedures in sensitive areas like the head and neck.
If a patient achieves a complete clinical response, the question arises: is radical surgery always mandatory? Emerging evidence suggests that for many, the answer may soon be “no.”
Frequently Asked Questions
- What is the difference between adjuvant and neoadjuvant therapy?
- Adjuvant therapy is given after surgery to prevent recurrence, while neoadjuvant therapy is given before surgery to shrink the tumor and assess response.
- Why is neoadjuvant therapy considered more “precise”?
- It allows doctors to see how a patient’s specific tumor responds to the drug before committing to a major surgery, which helps in tailoring the treatment plan.
- Are there side effects to PD-1 blockade?
- Yes, as with all immunotherapies, immune-related adverse events can occur. Patients should discuss the risk-benefit profile with their medical team.
Are you or a loved one navigating a skin cancer diagnosis? Join the conversation in the comments below or subscribe to our oncology newsletter for the latest updates in immunotherapy research.
